Immune to Cancer: The CRI Blog
-
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
Sarcoma Awareness Month: Tackling Chordoma with Dr. Cassian Yee
CRI-Chordoma Foundation CLIP Investigator Dr. Cassian Yee is exploring how to design cell therapies for patients with…
-
AACR20 Day 2 Highlights: COVID-19, Adoptive Cell Therapy, and Checkpoint Immunotherapy Insights
The second day of AACR’s annual meeting heard from experts at cancer centers in COVID-19 hotspots around…
-
How Immunotherapy for Esophageal Cancer is Making an Impact
Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…
-
CICON19 Day 1 Update: Cancer Prevention and Combination Immunotherapy Strategies
Day 1 of CICON19 explored how checkpoint immunotherapy might be improved through combination strategies as well as…
-
ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News
The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…
-
ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy
The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…
-
Immunotherapy Combination Approved as First-Line Option for Patients with Advanced Triple-Negative Breast Cancer
Patients with advanced triple-negative breast cancer can now receive frontline treatment with immunotherapy in combination with chemotherapy.